Andrew J Boyle
Affiliation: University of Melbourne
- Is it time to burst the "balloon" for high-risk patients?Sukesh C Burjonroppa
Cardiology Division, Heart and Vascular Center, UCSF, San Francisco, CA 94143, USA
J Invasive Cardiol 19:347-8. 2007
- Use of a continuous-flow device in patients awaiting heart transplantationLeslie W Miller
University of Minnesota, Minneapolis, USA
N Engl J Med 357:885-96. 2007..Continuous-flow pumps are newer types of left ventricular assist devices developed to overcome some of these limitations...
- Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-upAndrew J Boyle
Department of Medicine, University of Melbourne, St Vincent s Hospital, Princes St, Fitzroy 3065, Victoria, Australia
Int J Cardiol 109:21-7. 2006..These results demonstrate the feasibility of G-CSF mobilization, leukapheresis and intracoronary transfer of CD34+ stem cells in patients with CIHD, but longer-term studies are required to ensure that this protocol is safe and effective...
- Additive effects of endothelial progenitor cells combined with ACE inhibition and beta-blockade on left ventricular function following acute myocardial infarctionAndrew J Boyle
University of Melbourne, Department of Medicine, St Vincent s Hospital, Fitzroy, Victoria, 3065, Australia
J Renin Angiotensin Aldosterone Syst 6:33-7. 2005..Clinical trials using stem cell therapy in conjunction with standard medical treatment are warranted...
- Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarctionAndrew J Boyle
Department of Medicine, St Vincent s Hospital, University of Melbourne, Melbourne, Princes Street, Fitzroy 3065, Vic, Australia
J Mol Cell Cardiol 39:213-21. 2005..PKC-inhibition with ruboxistaurin led to attenuation in both the pathological fibrosis and impaired cardiac function that follow experimental MI, suggesting a possible role for this agent in preventing post-infarction heart failure...
- The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogenAndrew M Wilson
University of Melbourne, Department of Medicine, St Vincent s Hospital, Princes St, Fitzroy, Melbourne, Victoria 3065, Australia
Int J Cardiol 106:291-7. 2006..We review the postulated roles of CRP in atherogenesis and prediction of vascular events, as well as discussing current recommendations for CRP testing in patients...
- Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemiaGuosheng Xiang
Department of Surgery, Columbia University Medical Center, New York, New York 10032, USA
J Biol Chem 280:39394-402. 2005..Strategies to inhibit VDUP1 expression and/or function during acute ischemic events may be beneficial to cardiac functional recovery and prevention of left ventricular remodeling...
- Early improvement in cardiac tissue perfusion due to mesenchymal stem cellsKarl H Schuleri
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Am J Physiol Heart Circ Physiol 294:H2002-11. 2008..Cardiac MRI-based measures of blood flow may be a useful tool to predict a successful myocardial regenerative process after MSC treatment...
- Assessment of a novel angiographic image stabilization system for percutaneous coronary interventionAndrew J Boyle
Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
J Interv Cardiol 20:153-7. 2007..We tested a novel system to stabilize angiographic images at the region of interest in order to assist during PCI...
- Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapyLuciano C Amado
Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Am Coll Cardiol 48:2116-24. 2006..The purpose of this study was to test the hypothesis, with noninvasive multimodality imaging, that allogeneic mesenchymal stem cells (MSCs) produce and/or stimulate active cardiac regeneration in vivo after myocardial infarction (MI)...
- Cardiac Stem Cell Therapy. Need for Optimization of Efficacy and Safety MonitoringPeter Oettgen
Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
Circulation 114:353-8. 2006
- Is stem cell therapy ready for patients? Stem Cell Therapy for Cardiac Repair. Ready for the Next Step Andrew J Boyle
Department of Medicine, Division of Cardiology, Institute for Cell Engineering, and Specialized Center for Cell Based Therapy, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Circulation 114:339-52. 2006
- Quantitative automated assessment of myocardial perfusion at cardiac catheterizationAndrew J Boyle
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Am J Cardiol 102:980-7. 2008..Further studies to assess the prognostic value of this technique are warranted...